Leukomelanoderma After Hydroquinone Use Described

This article originally appeared here.
Share this content:
Leukomelanoderma After Hydroquinone Use Described
Leukomelanoderma After Hydroquinone Use Described

WEDNESDAY, Aug. 23, 2017 (HealthDay News) -- In a case report published online Aug. 16 in the Journal of Dermatology, leukomelanoderma is described in patients using hydroquinone at a concentration of 10 percent.

Saki Yanagishita-Nakatsuji, from the Osaka City University Graduate School of Medicine in Japan, and colleagues present two cases of leukomelanoderma associated with probable allergic contact dermatitis. One case is of a 61-year-old woman referred for evaluation of pigmentary changes on her face. She had used 10 percent hydroquinone cream for two months on her face and neck. Well-demarcated hypopigmented macules and diffuse hyperpigmentation were noted on the face and neck; the pigmentary changes had mainly resolved at 17 months after discontinuing the cream.

A second woman, aged 49 years, was referred for pigmentary changes on the face. She had used 10 percent hydroquinone cream for melasma for seven years, followed by three years of 7 percent hydroquinone cream. On both cheeks, she exhibited circumscribed depigmented macules and reticulated hyperpigmented macules. The pigmentary changes showed improvement 10 months after discontinuing hydroquinone. In both cases, the hypopigmented skin did not have melan-A-positive melanocytes, and many melanophages were present in the upper dermis of the hyperpigmented skin; neither case had ochronosis.

"Leukomelanoderma arising from the use of hydroquinone-containing cream is uncommon," the authors write. "Here, we have shown that a pseudo-pigment network was present in the hyperpigmented areas."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »